Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

Dec 11, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2017 Prescription for Success Healthcare Conference on December 14, 2017 at 3:30 p.m....

More
Dec 1, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Topical Solution, 4% and 10%, with a proposed trade name of...

More
Nov 29, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive...

More
Nov 9, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies London Healthcare Conference on November 15, 2017 at 12:40 p.m. (GMT). A webcast of the...

More
Nov 6, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 first quarter ended September 30, 2017. "In recent weeks, we announced a number of very positive developments...

More
Nov 1, 2017

Lannett Company, Inc. (NYSE: LCI) today responded to the allegations in the amended civil complaint by a number of states' attorneys general pending in the U.S. District Court for the Eastern...

More
Oct 30, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S....

More
Oct 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 first quarter on Monday, November 6, 2017, after the market closes. Lannett management...

More
Oct 2, 2017
--Company Cleared to Market Prescription and OTC Generic Prevacid®--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lansoprazole...

More
Sep 27, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone and...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products